CL2019002527A1 - Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer. - Google Patents

Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer.

Info

Publication number
CL2019002527A1
CL2019002527A1 CL2019002527A CL2019002527A CL2019002527A1 CL 2019002527 A1 CL2019002527 A1 CL 2019002527A1 CL 2019002527 A CL2019002527 A CL 2019002527A CL 2019002527 A CL2019002527 A CL 2019002527A CL 2019002527 A1 CL2019002527 A1 CL 2019002527A1
Authority
CL
Chile
Prior art keywords
compounds
quinolin
cancer
treatment
refers
Prior art date
Application number
CL2019002527A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Kurt Gordon Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2019002527A1 publication Critical patent/CL2019002527A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA MEMORIA DESCRIPTIVA SE REFIERE EN GENERAL A COMPUESTOS DE FÓRMULA (I), Y SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS, DONDE R1 TIENE LOS SIGNIFICADOS DEFINIDOS EN LA PRESENTE. LA MEMORIA DESCRIPTIVA TAMBIÉN SE REFIERE AL USO DE COMPUESTOS DE FÓRMULA (I) Y SALES DE ESTOS PARA TRATAR O PREVENIR UNA ENFERMEDAD MEDIADA POR ATM, INCLUIDO EL CÁNCER. LA MEMORIA DESCRIPTIVA SE REFIERE ADEMÁS A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN COMPUESTOS DE TIPO IMIDAZO[4,5-C]QUINOLIN-2-ONA SUSTITUIDOS Y SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS; Y KITS QUE COMPRENDEN TALES COMPUESTOS Y SALES.
CL2019002527A 2017-03-16 2019-09-03 Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer. CL2019002527A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762472080P 2017-03-16 2017-03-16

Publications (1)

Publication Number Publication Date
CL2019002527A1 true CL2019002527A1 (es) 2019-11-22

Family

ID=61801891

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002527A CL2019002527A1 (es) 2017-03-16 2019-09-03 Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer.

Country Status (25)

Country Link
US (2) US20200087300A1 (es)
EP (1) EP3596076A1 (es)
JP (1) JP2020514344A (es)
KR (1) KR20190129923A (es)
CN (1) CN110431139B (es)
AU (1) AU2018234985B2 (es)
BR (1) BR112019018723A2 (es)
CA (1) CA3055258A1 (es)
CL (1) CL2019002527A1 (es)
CO (1) CO2019010029A2 (es)
CR (1) CR20190429A (es)
DO (1) DOP2019000228A (es)
EA (1) EA038233B1 (es)
EC (1) ECSP19066134A (es)
IL (1) IL269272A (es)
JO (1) JOP20190209A1 (es)
MA (1) MA49884A (es)
MX (1) MX2019010898A (es)
NI (1) NI201900094A (es)
PE (1) PE20191486A1 (es)
PH (1) PH12019502086A1 (es)
SG (1) SG11201908065YA (es)
TW (1) TW201843151A (es)
UA (1) UA124554C2 (es)
WO (1) WO2018167203A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV15575A (lv) 2019-12-20 2021-06-20 Latvijas Organiskās Sintēzes Institūts Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
WO2021260580A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
JP5596137B2 (ja) * 2009-06-04 2014-09-24 ノバルティス アーゲー １Ｈ−イミダゾ［４，５−ｃ］キノリノン誘導体
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (es) * 2014-05-08 2018-04-21
RS62082B1 (sr) * 2015-04-02 2021-08-31 Merck Patent Gmbh Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer

Also Published As

Publication number Publication date
UA124554C2 (uk) 2021-10-05
JOP20190209A1 (ar) 2019-09-12
NI201900094A (es) 2020-03-18
ECSP19066134A (es) 2019-09-30
BR112019018723A2 (pt) 2020-04-07
PE20191486A1 (es) 2019-10-18
US20210347775A1 (en) 2021-11-11
KR20190129923A (ko) 2019-11-20
IL269272A (en) 2019-11-28
CR20190429A (es) 2019-11-12
MA49884A (fr) 2020-06-24
EA201992090A1 (ru) 2020-03-06
CA3055258A1 (en) 2018-09-20
AU2018234985B2 (en) 2020-04-02
DOP2019000228A (es) 2019-09-30
SG11201908065YA (en) 2019-09-27
EP3596076A1 (en) 2020-01-22
EA038233B1 (ru) 2021-07-28
WO2018167203A1 (en) 2018-09-20
AU2018234985A1 (en) 2019-10-24
TW201843151A (zh) 2018-12-16
CO2019010029A2 (es) 2019-09-30
MX2019010898A (es) 2019-11-07
JP2020514344A (ja) 2020-05-21
CN110431139A (zh) 2019-11-08
US20200087300A1 (en) 2020-03-19
CN110431139B (zh) 2022-07-05
PH12019502086A1 (en) 2020-03-09

Similar Documents

Publication Publication Date Title
CL2018001146A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
SV2018005680A (es) Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
CL2019002527A1 (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer.
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY36285A (es) Compuestos que inhiben la proteína mcl-1
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
AR100431A1 (es) Compuestos de pladienolida piridina y métodos de uso
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos